-+ 0.00%
-+ 0.00%
-+ 0.00%

BOEHRINGER INGELHEIM’S SURVODUTIDE ACHIEVES UP TO 13.1% WEIGHT LOSS IN NEW PHASE III TRIAL, ALONGSIDE SIGNIFICANT IMPROVEMENTS IN GLYCEMIC CONTROL IN PEOPLE WITH OBESITY AND TYPE 2 DIABETES

Reuters·10/01/2026 07:32:14